M&A Deal Summary

ADVANZ PHARMA Acquires Pinnacle Biologics

On December 24, 2013, ADVANZ PHARMA acquired life science company Pinnacle Biologics

Acquisition Highlights
  • This is ADVANZ PHARMA’s 1st transaction in the Life Science sector.
  • This is ADVANZ PHARMA’s 1st transaction in the United States.
  • This is ADVANZ PHARMA’s 1st transaction in Illinois.

M&A Deal Summary
Date 2013-12-24
Target Pinnacle Biologics
Sector Life Science
Buyer(s) ADVANZ PHARMA
Deal Type Add-on Acquisition
Advisor(s) Torreya Partners LLC (Financial)

Target

Pinnacle Biologics

Bannockburn, Illinois, United States
Pinnacle Biologics, Inc. biopharmaceutical research and development company specializing in orphan diseases.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ADVANZ PHARMA

London, United Kingdom
Category Company
Founded 1963
Sector Life Science
Employees675
Revenue 508M USD (2019)
DESCRIPTION

ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines with direct sales access in Europe and a global distribution network. ADVANZ PHARMA was founded in 1963 and is based in London, United Kingdom.

DEAL STATS #
Overall 1 of 6
Sector (Life Science) 1 of 4
Type (Add-on Acquisition) 1 of 3
State (Illinois) 1 of 1
Country (United States) 1 of 3
Year (2013) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-03-20 Donnatal

United States

Donnatal provides Donnatal, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis. It comes in two formulations: immediate release Donnatal Tablets, and immediate release Donnatal Elixir, a liquid.

Buy $200M
Mergr

Product

Company

Legal